- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01464697
Progesterone for Perimenopausal Night Sweats
Oral Micronized Progesterone for Perimenopausal Vasomotor Symptoms
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Participation from home or in-person at University of British Columbia/Centre for Menstrual Cycle and Ovulation Research (CeMCOR)/Women's Health Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Between 35-58 years of age
- At least 4 vasomotor symptoms (VMS) per day, on average, for at least 2/4 weeks or at least 56 over a four-week period. In addition, women should report having VMS of moderate or severe rather than mild intensity. Women reporting fewer VMS than this, but who report night sweats that awaken them from sleep on two or more nights per week will also be included.
- Perimenopausal status either based on irregularity of menstrual periods, or by onset of new perimenopausal symptoms in women with regular periods.
- At least one menstrual period within 12 months of study enrollment
- Ability and willingness to complete the Daily Perimenopause Hot Flush Calendar recording instrument.
- Ability to understand, speak, read and write English.
- Women who are at high risk for breast cancer (ie first degree relative with breast cancer, known/suspected history of breast cancer) will be required to have a normal mammogram and clinical breast examination within 12 months of study enrollment.
Exclusion Criteria:
- VMS without perimenopausal etiology.
- Women who have had a hysterectomy and/or ovariectomy.
- Peanut allergy (because peanut oil is used in the progesterone formulation.)
- Current or recent (within the last 6-mos.) use of hormonal therapies (estrogen, progesterone, hormonal contraceptives, hormonal fertility treatments), or plans to initiate use during the study period. Two exceptions: women using progestin-releasing intrauterine device (IUD) will not be excluded as it is felt that level of hormone released will not have an effect on VMS and women taking very low-dose transdermal progesterone therapies who have VMS and meet inclusion criteria will be considered on a case-by-case basis. If enrolled, women with these exclusion exceptions will be required to continue and document use of these therapies throughout the entire trial.
- Planned pregnancy or fertility treatment during the study period.
- Women who are breastfeeding.
- Participants with a score greater or equal to 15 on the Personal Health Questionnaire (PHQ-9) will be assessed on a case-by-case basis. Women assessed as needing further investigation and/or treatment for depression will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo Comparator
Placebo
|
placebo comparator, taken as 3 round capsules at bedtime daily for 12 weeks
|
Experimental: oral micronized progesterone
Oral micronized progesterone is Prometrium 300 mg at bedtime daily
|
300 mg as 3-100 mg capsules taken orally at bedtime daily for 12 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vasomotor Symptoms (VMS)/ VMS Score - at 12 Weeks
Time Frame: 12 weeks
|
Participants will complete a daily calendar (Daily Perimenopause Hot Flush Calendar) to record frequency (actual number) and severity (quantified by ordinal scale ie 0=none to 4=extreme) of hot flushes and night sweats. The VMS Score will be calculated as follows: Daily VMS Score = (# night sweats) x (severity) + (#hot flushes) x (severity). Outcome is the average daily VMS Score during the final 28 days of therapy, to be analysed with 28-day run-in scores as covariate. |
12 weeks
|
Frequency of VMS
Time Frame: 12 weeks
|
Frequency (count) of hot flushes/hot flashes and night sweats per day from prospective daily calendar records.
Outcome is the average daily VMS Frequency (day + night) during the final 28 days of therapy, to be analysed with 28-day run-in scores as covariate.
|
12 weeks
|
Severity of VMS
Time Frame: 12 weeks
|
Severity (0-4, 0=no intensity, 4=extreme intensity) of hot flushes/hot flashes and night sweats per day from prospective daily calendar records.
Daily summary score is the maximum of daytime and nighttime severity.
Outcome is the average daily severity during the final 28 days of therapy, to be analysed with 28-day run-in scores as covariate.
|
12 weeks
|
VMS Score by Early Perimenopause
Time Frame: 12 weeks
|
subgroup analysis of VMS Score by Early Perimenopause (no skipped period or <60 day cycle length).
Outcome is the average daily VMS Score during the final 28 days of therapy, to be analysed with 28-day run-in scores as covariate.
Participants will complete a daily calendar (Daily Perimenopause Hot Flush Calendar) to record frequency (actual number) and severity (quantified by ordinal scale ie 0=none to 4=extreme) of hot flushes and night sweats.
The VMS Score will be calculated as follows: Daily VMS Score = (# night sweats) x (severity) + (#hot flushes) x (severity).
|
12 weeks
|
VMS Score by Late Perimenopause
Time Frame: 12 weeks
|
subgroup analysis of VMS Score by Late Perimenopause (those with skipped or ≥60 day cycle lengths).
Outcome is the average daily VMS Score during the final 28 days of therapy, to be analysed with 28-day run-in scores as covariate.
Participants will complete a daily calendar (Daily Perimenopause Hot Flush Calendar) to record frequency (actual number) and severity (quantified by ordinal scale ie 0=none to 4=extreme) of hot flushes and night sweats.
The VMS Score will be calculated as follows: Daily VMS Score = (# night sweats) x (severity) + (#hot flushes) x (severity).
|
12 weeks
|
Subgroup Analysis for Those With Frequent and Severe VMS - VMS Score
Time Frame: 12 weeks
|
VMS Score for those with more frequent (≥7 per day and moderate to severe episodes of intensity 2-4) at baseline. Participants will complete a daily calendar (Daily Perimenopause Hot Flush Calendar) to record frequency (actual number) and severity (quantified by ordinal scale ie 0=none to 4=extreme) of hot flushes and night sweats. The VMS Score will be calculated as follows: Daily VMS Score = (# night sweats) x (severity) + (#hot flushes) x (severity). |
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sleep Problems
Time Frame: 12 weeks
|
Daily average rating of sleep problems (0-4) from prospective daily calendar records. Outcome is the average daily rating during the final 28 days of therapy, to be analysed with 28-day run-in scores as covariate. Scale name: Sleep Problems (4=Worst, 0=None) |
12 weeks
|
Anxiety
Time Frame: 12 weeks
|
Daily average rating of anxiety (0-4) from prospective daily calendar records.
Outcome is the average daily rating during the final 28 days of therapy, to be analysed with 28-day run-in scores as covariate.
Scale name: Anxiety (4=Worst, 0=None)
|
12 weeks
|
Women's Perceived Changes in Daytime Hot Flushes for Whole Population
Time Frame: 12 weeks
|
Women's Perceived Changes Questionnaire of changes (from -5 to 0 to +5) in Daytime Hot Flushes (both number and severity) as recorded on the Final Questionnaire. Scale Name: Daytime Hot Flush Change Decrease is -5 to -1; No change is 0; Increase is +1 to +5. This is women's perception of the change from run-in to when they recorded it at the end of the trial (at 12 weeks). No calculation is needed. |
12 weeks
|
Women's Perceived Changes in Night Sweats for Whole Population
Time Frame: 12 weeks
|
Women's Perceived Changes Questionnaire of changes (from -5 to 0 to +5) in Nighttime Night Sweats (both number and severity) as recorded on the Final Questionnaire. Scale Name: Night Sweats Change Decrease is -5 to -1; No change is 0; Increase is +1 to +5. This is women's perception of the change from run-in to when they recorded it at the end of the trial (at 12 weeks). No calculation is needed. |
12 weeks
|
Women's Perceived Changes in Quality of Sleep for Whole Population
Time Frame: 12 weeks
|
Women's Perceived Changes Questionnaire of changes (from -5 to 0 to +5) in the quality of sleep over the three months of the trial as assessed by the Final Questionnaire based on their random assignment to the progesterone or placebo arms of this RCT (Randomized Controlled Trial) and by Early/Late perimenopause. Scale Name: Quality of Sleep Change Decrease is -5 to -1; No change is 0; Increase is +1 to +5. This is women's perception of the change from run-in to when they recorded it at the end of the trial (at 12 weeks). No calculation is needed. |
12 weeks
|
Perception of Interference of Overall Perimenopausal Changes With Usual Activities in Women
Time Frame: 12 weeks
|
Final perceptions of interference of overall perimenopausal changes with usual activities (as recorded by the CeMCOR PIQ - Centre for Menstrual Cycle and Ovulation Research Perimenopause Interference Questionnaire) at 12 weeks in women randomized to the progesterone versus to placebo. Scale Name: Perceived Interference Score: 100 mm line (0 = No Interference; 100 = Severe Interference) |
12 weeks
|
Perception of Interference of Overall Perimenopausal Changes With Usual Activities in Women - Early Perimenopause
Time Frame: 12 weeks
|
Final perceptions of interference of overall perimenopausal changes with usual activities (as recorded by the CeMCOR Perimenopause Interference Questionnaire [CeMCOR PIQ]) at 12 weeks in women randomized to the progesterone versus to placebo. Scale Name: Perceived Interference Score: 100 mm line (0 = No Interference; 100 = Severe Interference) |
12 weeks
|
Perception of Interference of Overall Perimenopausal Changes With Usual Activities in Women - Late Perimenopause
Time Frame: 12 weeks
|
Final perceptions of interference of overall perimenopausal changes with usual activities (as recorded by the CeMCOR Perimenopause Interference Questionnaire [CeMCOR PIQ]) at 12 weeks in women randomized to the progesterone versus to placebo. Scale Name: Perceived Interference Score: 100 mm line (0 = No Interference; 100 = Severe Interference) |
12 weeks
|
Perception of Interference of Perimenopausal Body Changes With Usual Activities in Women
Time Frame: 12 weeks
|
Final perceptions of interference of perimenopausal body changes with usual activities (as recorded by the CeMCOR Perimenopause Interference Questionnaire [CeMCOR PIQ]) in women randomized to the progesterone versus to placebo. Scale Name: Perceived Interference Score: 100 mm line (0 = No Interference; 100 = Severe Interference) |
12 weeks
|
Perception of Interference of Perimenopausal Mood Changes With Usual Activities in Women
Time Frame: 12 weeks
|
Final perceptions of interference of perimenopausal mood changes with usual activities (as recorded by the CeMCOR Perimenopause Interference Questionnaire [CeMCOR PIQ]) in women randomized to the progesterone versus to placebo. Scale Name: Perceived Interference Score: 100 mm line (0 = No Interference; 100 = Severe Interference) |
12 weeks
|
Women's Perceived Changes in Daytime Hot Flushes in Early Perimenopause
Time Frame: 12 weeks
|
Women's Perceived Changes Questionnaire of changes (from -5 to 0 to +5) in Daytime Hot Flushes (both number and severity) as recorded on the Final Questionnaire and by subgroup for Early Perimenopause. Scale Name: Perceived Daytime Hot Flush Change Decrease is -5 to -1; No change is 0; Increase is +1 to +5. |
12 weeks
|
Women's Perceived Changes in Night Sweats in Early Perimenopause
Time Frame: 12 weeks
|
Women's Perceived Changes Questionnaire of changes (from -5 to 0 to +5) in Nighttime Night Sweats (both number and severity) as recorded on the Final Questionnaire and by subgroup for Early Perimenopause. Scale Name: Perceived Night Sweats Change Decrease is -5 to -1; No change is 0; Increase is +1 to +5. |
12 weeks
|
Women's Perceived Changes in Daytime Hot Flushes in Late Perimenopause
Time Frame: 12 weeks
|
Women's Perceived Changes Questionnaire of changes (from -5 to 0 to +5) in Daytime Hot Flushes (both number and severity) as recorded on the Final Questionnaire and by subgroup for Late Perimenopause. Scale Name: Perceived Daytime Hot Flush Change Decrease is -5 to -1; No change is 0; Increase is +1 to +5. |
12 weeks
|
Women's Perceived Changes in Night Sweats in Late Perimenopause
Time Frame: 12 weeks
|
Women's Perceived Changes Questionnaire of changes (from -5 to 0 to +5) in Nighttime Night Sweats (both number and severity) as recorded on the Final Questionnaire and by subgroup for Late Perimenopause. Scale Name: Perceived Night Sweats Change Decrease is -5 to -1; No change is 0; Increase is +1 to +5. |
12 weeks
|
Depression Related to Progesterone Therapy in Whole Population
Time Frame: 12 weeks
|
Final PHQ9 (Personal Health Questionnaire 9) Score for Depression related to progesterone therapy in perimenopause will be assessed based on the Personal Health Questionnaire-9 (PHQ-9) score changes within-woman from baseline to the end-of-trial on progesterone compared with placebo. Scale Name: PHQ9 Scale (0 = No Depression; 27 = Severe Depression) |
12 weeks
|
Depression Related to Progesterone Therapy in Early Perimenopause
Time Frame: 12 weeks
|
Final PHQ9 Score for Depression related to progesterone therapy in Early Perimenopause will be assessed based on the Personal Health Questionnaire-9 (PHQ-9) score changes within-woman from baseline to the end-of-trial on progesterone compared with placebo. Scale Name: PHQ9 Scale (0 = No Depression; 27 = Severe Depression) |
12 weeks
|
Depression Related to Progesterone Therapy in Late Perimenopause
Time Frame: 12 weeks
|
Final PHQ9 Score for Depression related to progesterone therapy in Late Perimenopause will be assessed based on the Personal Health Questionnaire-9 (PHQ-9) score changes within-woman from baseline to the end-of-trial on progesterone compared with placebo. Scale Name: PHQ9 Scale (0 = No Depression; 27 = Severe Depression) |
12 weeks
|
Percentage of Women With Perceived Changes in Menstrual Flow
Time Frame: 12 weeks
|
Menstrual flow related to progesterone therapy in perimenopause was assessed based on Women's Perceived Changes Questionnaire of changes in the experience of menstrual flow/vaginal bleeding from the Final Questionnaire.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jerilynn C Prior, MD, FRCPC, University of British Columbia
Publications and helpful links
General Publications
- Prior JC, Hitchcock, CL. Progesterone for Vasomotor Symptoms: A 12-week Randomized, Masked Placebo-controlled Trial in Healthy, Normal-Weight Women 1-10 Years Since Final Menstrual Flow (Abstract). Endocrine Reviews 31(3): S51, 2010.
- Hitchcock CL, Prior JC. Oral micronized progesterone for vasomotor symptoms--a placebo-controlled randomized trial in healthy postmenopausal women. Menopause. 2012 Aug;19(8):886-93. doi: 10.1097/gme.0b013e318247f07a.
- Prior JC, Cameron A, Hitchcock CL, et al. Oral Micronized Progesterone Beneficial for Perimenopausal Hot Flushes/Flashes and Night Sweats. Endocrine Reviews 2018;39(2) Abstract-oral presentation at Endocrine Society Conference, Chicago, 2018.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H10-02975
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hot Flushes
-
A. Vogel AGTerminatedMenopausal Hot FlushesSwitzerland
-
Solvay PharmaceuticalsCompletedHot Flushes, Menopause, PostmenopauseUnited States, Canada, Russian Federation
-
EndoCeutics Inc.CompletedVasomotor Symptoms | Hot FlushesCanada
-
University of PennsylvaniaForest LaboratoriesCompleted
-
Liverpool John Moores UniversityBritish Heart FoundationRecruiting
-
BionovoUnknown
-
Donesta BioscienceSynteractHCRCompleted
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)CompletedHot Flashes | Hot FlushesUnited States
-
Warner ChilcottCompletedHormone Replacement TherapyUnited States
-
Northwestern UniversityUniversity of Illinois at ChicagoCompleted
Clinical Trials on Oral micronized progesterone
-
University of British ColumbiaUnknown
-
CRG UZ BrusselKU Leuven; Abbott; Universitätsklinikum Hamburg-EppendorfCompletedInfertility | Infertility, Female | Dydrogesterone | Genital Diseases, Female | Progesterone | Hormones | Physiological Effects of Drugs | Genital Diseases, Male | Hormones, Hormone Substitutes, and Hormone Antagonists | ProgestinsBelgium
-
University of British ColumbiaCompletedPerimenopause | Menstrual CrampsCanada
-
University of VirginiaEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Heilongjiang University of Chinese MedicineRecruitingThreatened MiscarriageChina
-
University of VirginiaEunice Kennedy Shriver National Institute of Child Health and Human Development...TerminatedFemale Reproductive PhysiologyUnited States
-
Fetal Medicine FoundationCompleted
-
CRG UZ BrusselActive, not recruitingInfertility, Female | Frozen Embryo Transfer | Hormone Replacement Therapy | DydrogesteroneBelgium
-
Duramed ResearchCompleted
-
Hospital de Clinicas de Porto AlegreUnknownMenopause | Hormone Replacement TherapyBrazil